DR Sifat Sharmin
Senior Research Fellow, Clinical Outcomes Research
Department of Medicine
152 Scholarly works
4 Projects
HIGHLIGHTS
2026
Journal article
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
DOI: 10.1007/s40263-026-01287-82026
Journal article
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability
DOI: 10.1212/WNL.00000000002180562026
Journal article
Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis
DOI: 10.1177/135245852614218162026
Journal article
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
DOI: 10.1093/brain/awaf2862026
Journal article
Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis
DOI: 10.1111/ene.705052023
Research grants (other domestic)
Hematopoietic Stem Cell Transplantation to Prevent & Reverse MS Disability
2022
Research Grant
MSBase Foundation Fellowship 2022
RECENT SCHOLARLY WORKS
2026
Journal article
Managing reactivation of multiple sclerosis during treatment with natalizumab
DOI: 10.1177/135245852513986822026
Journal article
A community-validated tool for clinical outcome calculation in multiple sclerosis: Consensus development and scenario-specific recommendations
DOI: 10.1177/135245852614784922026
Journal article
Causal effects of multiple sclerosis therapies in left-truncated registry data
DOI: 10.1177/135245852614599432026
Journal article
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
DOI: 10.1136/jnnp-2026-3384242025
Conference Proceedings
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
DOI: 10.1136/jnnp-2025-336343
RECENT PROJECTS
2026
Research contracts (non-grants)
Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for Patients With Relapsing Remitting Multiple Sclerosis (RAM-MS)
2021
Internal Research Grant
High-Efficacy Therapy to Prevent Disability in Aggressive Multiple Sclerosis.